Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Fasoracetam - Avalo Therapeutics

Alternative Names: AEVI-001; Fasoracetam; LAM 105; MDGN-001; NFC 1; NS 105

Latest Information Update: 30 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer Cerecor
  • Class Antiepileptic drugs; Neuroprotectants; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Metabotropic glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Autistic disorder; Cognition disorders; DiGeorge syndrome; Major depressive disorder

Most Recent Events

  • 26 Aug 2021 Cerecor is now called Avalo Therapeutics
  • 03 Feb 2020 Aevi Genomic Medicine has been acquired and merged into Cerecor
  • 31 Dec 2018 Discontinued - Phase-I for Autistic disorder in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now